Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Der Nervenarzt
Erschienen in: Der Nervenarzt 3/2015

01.03.2015 | CME Zertifizierte Fortbildung

Behandlung der Depression bei koronarer Herzerkrankung

verfasst von: Dr. A. Agorastos, F. Lederbogen, C. Otte

Erschienen in: Der Nervenarzt | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Depression und koronare Herzerkrankung (KHK) sind führende Ursachen der globalen Krankheitslast und weisen eine hohe Komorbidität auf. Zudem stellt die Depression einen unabhängigen Risikofaktor für einen ungünstigeren Verlauf der KHK dar. Umgekehrt kann eine erfolgreiche Depressionsbehandlung zur Reduktion des kardialen Risikos führen. Aktuell stehen unterschiedliche Therapieoptionen zur Behandlung der Depression bei Patienten mit komorbider KHK zur Verfügung, die stufenweise oder kombiniert Anwendung finden. Eine besondere Bedeutung kommt dabei dem Selbstmanagement, der Psychotherapie, der Pharmakotherapie und neuen Versorgungsmodellen zu. Dieser Artikel bietet eine Übersicht zur Epidemiologie und Pathophysiologie der Depression bei Patienten mit KHK sowie zur Effektivität und Sicherheit verschiedener Therapieoptionen.
Literatur
1.
Vos T, Flaxman AD, Naghavi M et al (2012) Years lived with disability (ylds) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the global burden of disease study 2010. Lancet 380:2163–2196CrossRefPubMed
2.
Kuehl LK, Penninx BW, Otte C (2012) Depression: risk factor for cardiovascular disease. Nervenarzt 83:1379–1384CrossRefPubMed
3.
Whooley MA, Wong JM (2013) Depression and cardiovascular disorders. Annu Rev Clin Psychol 9:327–354CrossRefPubMed
4.
5.
Lichtman JH, Froelicher ES, Blumenthal JA et al (2014) Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation 129:1350–1369CrossRefPubMed
6.
Nicholson A, Kuper H, Hemingway H (2006) Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. Eur Heart J 27:2763–2774CrossRefPubMed
7.
Melle JP van, Jonge P de, Spijkerman TA et al (2004) Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med 66:814–822CrossRefPubMed
8.
Meijer A, Conradi HJ, Bos EH et al (2013) Adjusted prognostic association of depression following myocardial infarction with mortality and cardiovascular events: individual patient data meta-analysis. Br J Psychiatry 203:90–102CrossRefPubMed
9.
Bush DE, Ziegelstein RC, Tayback M et al (2001) Even minimal symptoms of depression increase mortality risk after acute myocardial infarction. Am J Cardiol 88:337–341CrossRefPubMed
10.
Stewart JC, Perkins AJ, Callahan CM (2014) Effect of collaborative care for depression on risk of cardiovascular events: data from the impact randomized controlled trial. Psychosom Med 76:29–37CrossRefPubMedCentralPubMed
11.
Lederbogen F, Strohle A (2012) Stress, mental disorders and coronary heart disease. Nervenarzt 83:1448–1457CrossRefPubMed
12.
Kemp AH, Quintana DS, Gray MA et al (2010) Impact of depression and antidepressant treatment on heart rate variability: a review and meta-analysis. Biol Psychiatry 67:1067–1074CrossRefPubMed
13.
Otte C, Neylan TC, Pipkin SS et al (2005) Depressive symptoms and 24-hour urinary norepinephrine excretion levels in patients with coronary disease: findings from the heart and soul study. Am J Psychiatry 162:2139–2145CrossRefPubMedCentralPubMed
14.
Penninx BW, Milaneschi Y, Lamers F, Vogelzangs N (2013) Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile. BMC Med 11:129CrossRefPubMedCentralPubMed
15.
Ladwig KH, Marten-Mittag B, Lowel H et al (2005) C-reactive protein, depressed mood, and the prediction of coronary heart disease in initially healthy men: results from the monica-kora augsburg cohort study 1984–1998. Eur Heart J 26:2537–2542CrossRefPubMed
16.
Bruce EC, Musselman DL (2005) Depression, alterations in platelet function, and ischemic heart disease. Psychosom Med 67(Suppl 1):S34–S36CrossRefPubMed
17.
18.
Bondy B (2007) Common genetic factors for depression and cardiovascular disease. Dialogues Clin Neurosci 9:19–28PubMedCentralPubMed
19.
Hare DL, Toukhsati SR, Johansson P, Jaarsma T (2014) Depression and cardiovascular disease: a clinical review. Eur Heart J 35:1365–1372CrossRefPubMed
20.
Pogosova N, Saner H, Pedersen SS et al (2014) Psychosocial aspects in cardiac rehabilitation: from theory to practice. A position paper from the cardiac rehabilitation section of the european association of cardiovascular prevention and rehabilitation of the European Society of Cardiology. Eur J Prev Cardiol [Epub ahead of print]
21.
Ladwig KH, Lederbogen F, Albus C et al (2014) Position paper on the importance of psychosocial factors in cardiology: update 2013. Ger Med Sci 12:Doc09PubMedCentralPubMed
22.
Whooley MA, Jonge P de, Vittinghoff E et al (2008) Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. JAMA 300:2379–2388CrossRefPubMedCentralPubMed
23.
Gehi A, Haas D, Pipkin S, Whooley MA (2005) Depression and medication adherence in outpatients with coronary heart disease: findings from the heart and soul study. Arch Intern Med 165:2508–2513CrossRefPubMedCentralPubMed
24.
Win S, Parakh K, Eze-Nliam CM et al (2011) Depressive symptoms, physical inactivity and risk of cardiovascular mortality in older adults: the cardiovascular health study. Heart 97:500–505CrossRefPubMedCentralPubMed
25.
26.
Tatoulis J, Psychosocial Risk Factors Expert Working Group of the National Heart Foundation of, A (2014) The rationale for depression screening in patients with coronary heart disease. On behalf of the psychosocial risk factors expert working group of the national heart foundation of Australia. J Psychosom Res 76:172–173CrossRefPubMed
27.
Elderon L, Smolderen KG, Na B, Whooley MA (2011) Accuracy and prognostic value of American Heart Association: recommended depression screening in patients with coronary heart disease: data from the heart and soul study. Circ Cardiovasc Qual Outcomes 4:533–540CrossRefPubMed
28.
Burton C, Simpson C, Anderson N (2013) Diagnosis and treatment of depression following routine screening in patients with coronary heart disease or diabetes: a database cohort study. Psychol Med 43:529–537CrossRefPubMed
29.
Albus C, Ladwig KH, Herrmann-Lingen C (2014) Psychocardiology: clinically relevant recommendations regarding selected cardiovascular diseases. Dtsch Med Wochenschr 139:596–601CrossRefPubMed
30.
DGPPN, BÄK, KBV et al (2009) S3-leitlinie/nationale versorgungsleitlinie unipolare depression-kurzfassung, 1. Aufl. DGPPN, ÄZQ, AWMF, Berlin
31.
Rutledge T, Redwine LS, Linke SE, Mills PJ (2013) A meta-analysis of mental health treatments and cardiac rehabilitation for improving clinical outcomes and depression among patients with coronary heart disease. Psychosom Med 75:335–349CrossRefPubMed
32.
Blumenthal JA, Babyak MA, O’Connor C et al (2012) Effects of exercise training on depressive symptoms in patients with chronic heart failure: the hf-action randomized trial. JAMA 308:465–474PubMedCentralPubMed
33.
Herring MP, Puetz TW, O’Connor PJ, Dishman RK (2012) Effect of exercise training on depressive symptoms among patients with a chronic illness: a systematic review and meta-analysis of randomized controlled trials. Arch Intern Med 172:101–111CrossRefPubMed
34.
Blumenthal JA, Sherwood A, Babyak MA et al (2012) Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the upbeat (understanding the prognostic benefits of exercise and antidepressant therapy) study. J Am Coll Cardiol 60:1053–1063CrossRefPubMedCentralPubMed
35.
Baumeister H, Hutter N, Bengel J (2011) Psychological and pharmacological interventions for depression in patients with coronary artery disease. Cochrane Database Syst Rev 9:CD008012 (Online)PubMed
36.
Dickens C, Cherrington A, Adeyemi I et al (2013) Characteristics of psychological interventions that improve depression in people with coronary heart disease: a systematic review and meta-regression. Psychosom Med 75:211–221CrossRefPubMed
37.
Whalley B, Rees K, Davies P et al (2011) Psychological interventions for coronary heart disease. Cochrane Database Syst Rev 8:CD002902 (Online)PubMed
38.
Glassman AH, O’Connor CM, Califf RM et al (2002) Sertraline treatment of major depression in patients with acute mi or unstable angina. JAMA 288:701–709CrossRefPubMed
39.
40.
Zimmermann-Viehoff F, Kuehl LK, Danker-Hopfe H et al (2014) Antidepressants, autonomic function and mortality in patients with coronary heart disease: data from the heart and soul study. Psychol Med 44:2975–2984CrossRefPubMed
41.
Ziegelstein RC, Meuchel J, Kim TJ et al (2007) Selective serotonin reuptake inhibitor use by patients with acute coronary syndromes. Am J Med 120:525–530CrossRefPubMed
42.
Licht CM, Penninx BW, Geus EJ de (2012) Effects of antidepressants, but not psychopathology, on cardiac sympathetic control: a longitudinal study. Neuropsychopharmacology 37:2487–2495CrossRefPubMedCentralPubMed
43.
Hanash JA, Hansen BH, Hansen JF et al (2012) Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome: results from the depression in patients with coronary artery disease (decard) trial. J Cardiovasc Pharmacol 60:397–405CrossRefPubMed
44.
Jiang W, Velazquez EJ, Kuchibhatla M et al (2013) Effect of escitalopram on mental stress-induced myocardial ischemia: results of the remit trial. JAMA 309:2139–2149CrossRefPubMed
45.
Mazza M, Lotrionte M, Biondi-Zoccai G et al (2010) Selective serotonin reuptake inhibitors provide significant lower re-hospitalization rates in patients recovering from acute coronary syndromes: evidence from a meta-analysis. J Psychopharmacol 24:1785–1792CrossRefPubMed
46.
Berkman LF, Blumenthal J, Burg M et al (2003) Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhancing recovery in coronary heart disease patients (enrichd) randomized trial. JAMA 289:3106–3116CrossRefPubMed
47.
Xiong GL, Jiang W, Clare R et al (2006) Prognosis of patients taking selective serotonin reuptake inhibitors before coronary artery bypass grafting. Am J Cardiol 98:42–47CrossRefPubMed
48.
Weeke P, Jensen A, Folke F et al (2012) Antidepressant use and risk of out-of-hospital cardiac arrest: a nationwide case-time-control study. Clin Pharmacol Ther 92:72–79CrossRefPubMed
49.
Rieckmann N, Kronish IM, Shapiro PA et al (2013) Serotonin reuptake inhibitor use, depression, and long-term outcomes after an acute coronary syndrome: a prospective cohort study. JAMA Intern Med 173:1150–1151CrossRefPubMedCentralPubMed
50.
Strubel T, Birkhofer A, Mossmer G, Forstl H (2010) SSRI – treatment and bleeding. What risks do we take? Nervenarzt 81:549–555CrossRefPubMed
51.
Kemp AH, Brunoni AR, Santos IS et al (2014) Effects of depression, anxiety, comorbidity, and antidepressants on resting-state heart rate and its variability: an ELSA-Brasil Cohort Baseline Study. Am J Psychiatry [Epub ahead of print]
52.
Beach SR, Kostis WJ, Celano CM et al (2014) Meta-analysis of selective serotonin reuptake inhibitor-associated qtc prolongation. J Clin Psychiatry 75:e441–e449CrossRefPubMed
53.
Funk KA, Bostwick JR (2013) A comparison of the risk of qt prolongation among ssris. Ann Pharmacother 47:1330–1341CrossRefPubMed
54.
Lesperance F, Frasure-Smith N, Koszycki D et al (2007) Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (create) trial. JAMA 297:367–379CrossRefPubMed
55.
Kim JM, Bae KY, Stewart R, Jung BO et al (2015) Escitalopram treatment for depressive disorder following acute coronary syndrome: A 24-week double-blind, placebo-controlled trial. J Clin Psychiatry 76(1):62–68CrossRefPubMed
56.
Jiang W, Davidson JR (2005) Antidepressant therapy in patients with ischemic heart disease. Am Heart J 150:871–881CrossRefPubMed
57.
Taylor D (2008) Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety. Acta Psychiatr Scand 118:434–442CrossRefPubMed
58.
Pizzi C, Rutjes AW, Costa GM et al (2011) Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am J Cardiol 107:972–979CrossRefPubMed
59.
Mavrides N, Nemeroff C (2013) Treatment of depression in cardiovascular disease. Depress Anxiety 30:328–341CrossRefPubMed
60.
O’Connor CM, Jiang W, Kuchibhatla M et al (2010) Safety and efficacy of sertraline for depression in patients with heart failure: Results of the sadhart-chf (sertraline against depression and heart disease in chronic heart failure) trial. J Am Coll Cardiol 56:692–699CrossRef
61.
Hamer M, Batty GD, Marmot MG et al (2011) Anti-depressant medication use and c-reactive protein: results from two population-based studies. Brain Behav Immun 25:168–173CrossRefPubMedCentralPubMed
62.
Reedt Dortland AK van, Giltay EJ, Veen T van et al (2010) Metabolic syndrome abnormalities are associated with severity of anxiety and depression and with tricyclic antidepressant use. Acta Psychiatr Scand 122:30–39
63.
Roose SP (2003) Treatment of depression in patients with heart disease. Biol Psychiatry 54:262–268CrossRefPubMed
64.
Honig A, Kuyper AM, Schene AH et al (2007) Treatment of post-myocardial infarction depressive disorder: a randomized, placebo-controlled trial with mirtazapine. Psychosom Med 69:606–613CrossRefPubMed
65.
Roose SP, Dalack GW, Glassman AH et al (1991) Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry 148:512–516CrossRefPubMed
66.
Terhardt J, Lederbogen F, Feuerhack A et al (2013) Heart rate variability during antidepressant treatment with venlafaxine and mirtazapine. Clin Neuropharmacol 36:198–202CrossRefPubMed
67.
Johnson EM, Whyte E, Mulsant BH et al (2006) Cardiovascular changes associated with venlafaxine in the treatment of late-life depression. Am J Geriatr Psychiatry 14:796–802CrossRefPubMed
68.
Schramm PJ, Poland RE, Rao U (2014) Bupropion response on sleep quality in patients with depression: implications for increased cardiovascular disease risk. Eur Neuropsychopharmacol 24:207–214CrossRefPubMedCentralPubMed
69.
Wernicke J, Lledo A, Raskin J et al (2007) An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf 30:437–455CrossRefPubMed
70.
Ho JM, Gomes T, Straus SE et al (2014) Adverse cardiac events in older patients receiving venlafaxine: a population-based study. J Clin Psychiatry 75:e552–e558CrossRefPubMed
71.
Dubovsky SL, Warren C (2009) Agomelatine, a melatonin agonist with antidepressant properties. Expert Opin Investig Drugs 18:1533–1540CrossRefPubMed
72.
Dubovsky SL (2014) Pharmacokinetic evaluation of vortioxetine for the treatment of major depressive disorder. Expert Opin Drug Metab Toxicol 10:759–766CrossRefPubMed
73.
Katon W, Russo J, Lin EH et al (2012) Cost-effectiveness of a multicondition collaborative care intervention: a randomized controlled trial. Arch Gen Psychiatry 69:506–514CrossRefPubMed
74.
75.
Gulliksson M, Burell G, Vessby B et al (2011) Randomized controlled trial of cognitive behavioral therapy vs standard treatment to prevent recurrent cardiovascular events in patients with coronary heart disease: Secondary prevention in uppsala primary health care project (suprim). Arch Intern Med 171:134–140CrossRefPubMed
76.
Albus C, Beutel ME, Deter HC et al (2011) A stepwise psychotherapy intervention for reducing risk in coronary artery disease (spirr-cad) – rationale and design of a multicenter, randomized trial in depressed patients with cad. J Psychosom Res 71:215–222CrossRefPubMed
77.
Albus C (2014) A stepwise psychotherapy intervention to reduce risk in coronary artery disease (spirr-cad) – results of a randomised, controlled multicentre trial. J Psychosom Res 76:495CrossRef
78.
Roncella A, Pristipino C, Cianfrocca C et al (2013) One-year results of the randomized, controlled, short-term psychotherapy in acute myocardial infarction (step-in-ami) trial. Int J Cardiol 170:132–139CrossRefPubMed
79.
Freedland KE, Skala JA, Carney RM et al (2009) Treatment of depression after coronary artery bypass surgery: a randomized controlled trial. Arch Gen Psychiatry 66:387–396CrossRefPubMed
80.
Barth J, Paul J, Harter M, Bengel J (2005) Inpatient psychotherapeutic treatment for cardiac patients with depression in germany – short term results. Psychosoc Med 2:Doc04PubMedCentralPubMed
81.
Strik JJ, Honig A, Lousberg R et al (2000) Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosom Med 62:783–789CrossRefPubMed
82.
McFarlane A, Kamath MV, Fallen EL et al (2001) Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. Am Heart J 142:617–623CrossRefPubMed
83.
Mohapatra PK, Kar N, Kar GC, Behera M (2005) Effectiveness of sertraline in treatment of depression in a consecutive sample of patients with acute myocardial infarction: six month prospective study on outcome. Clin Pract Epidemiol Ment Health 1:26CrossRefPubMedCentralPubMed
84.
Davidson KW, Bigger JT, Burg MM et al (2013) Centralized, stepped, patient preference-based treatment for patients with post-acute coronary syndrome depression: codiacs vanguard randomized controlled trial. JAMA Intern Med 173:997–1004CrossRefPubMedCentralPubMed
85.
Kronish IM, Rieckmann N, Burg MM et al (2012) The effect of enhanced depression care on adherence to risk-reducing behaviors after acute coronary syndromes: findings from the copes trial. Am Heart J 164:524–529CrossRefPubMedCentralPubMed
86.
Davidson KW, Rieckmann N, Clemow L et al (2010) Enhanced depression care for patients with acute coronary syndrome and persistent depressive symptoms: coronary psychosocial evaluation studies randomized controlled trial. Arch Intern Med 170:600–608CrossRefPubMedCentralPubMed
87.
Donohue JM, Belnap BH, Men A et al (2014) Twelve-month cost-effectiveness of telephone-delivered collaborative care for treating depression following cabg surgery: a randomized controlled trial. Gen Hosp Psychiatry 36:453–459CrossRefPubMed
88.
Huffman JC, Mastromauro CA, Beach SR et al (2014) Collaborative care for depression and anxiety disorders in patients with recent cardiac events: the management of sadness and anxiety in cardiology (mosaic) randomized clinical trial. JAMA Intern Med 174:927–935CrossRefPubMed
89.
Barley EA, Walters P, Haddad M et al (2014) The upbeat nurse-delivered personalized care intervention for people with coronary heart disease who report current chest pain and depression: a randomised controlled pilot study. PLoS One 9:e98704CrossRefPubMedCentralPubMed
90.
O’Neil A, Taylor B, Sanderson K et al (2014) Efficacy and feasibility of a tele-health intervention for acute coronary syndrome patients with depression: results of the „moodcare“ randomized controlled trial. Ann Behav Med 48:163–174CrossRef
91.
O’Neil A, Taylor B, Hare DL et al (2014) Long-term efficacy of a tele-health intervention for acute coronary syndrome patients with depression: 12-month results of the moodcare randomized controlled trial. Eur J Prev Cardiol [Epub ahead of print]
92.
Morgan MA, Coates MJ, Dunbar JA et al (2013) The trueblue model of collaborative care using practice nurses as case managers for depression alongside diabetes or heart disease: a randomised trial. BMJ Open 3
93.
Coventry PA, Lovell K, Dickens C et al (2013) Update on the collaborative interventions for circulation and depression (coincide) trial: changes to planned methodology of a cluster randomized controlled trial of collaborative care for depression in people with diabetes and/or coronary heart disease. Trials 14:136CrossRefPubMedCentralPubMed
Metadaten
Titel
Behandlung der Depression bei koronarer Herzerkrankung
verfasst von
Dr. A. Agorastos
F. Lederbogen
C. Otte
Publikationsdatum
01.03.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Der Nervenarzt / Ausgabe 3/2015
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI
https://doi.org/10.1007/s00115-014-4162-z

Weitere Artikel der Ausgabe 3/2015

Der Nervenarzt 3/2015 Zur Ausgabe

Nachruf

Nachruf auf Prof. Dr. Rainer Tölle

Originalien

Spiritualität bei schizophrenen Erkrankungen

Einführung zum Thema

Psychoonkologie

Mitteilungen der DGPPN

Mitteilungen der DGPPN 3/2015

Leitthema

Diagnose und Therapie neurokognitiver Störungen bei onkologischen Patienten

Originalien

Merkmale einer regionalen Pflichtversorgung in Deutschland

Neu in den Fachgebieten Neurologie und Psychiatrie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Bildnachweise